As biopharma organizations decrease their budgets and move away from a recruitment-centric approach, the need to develop existing talent to fill key technical skills gaps has never been more mission […]

With the launch of the FDA’s Project Optimus, and the evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has […]

Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving […]

The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent - or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent […]

With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects […]

2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with […]

Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only […]

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its […]

The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. Over three days, the summit brings […]

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling. As the FDA phases out animal testing […]

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition […]

The Longest Standing & Pre-Eminent European ADC Forum 16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers With traditional ADCs now fulfilling their potential […]

Across pharma, biotech, chemicals, FMCG, and beyond, laboratory leaders are facing the same challenge: how to turn the vision of a smart, digital lab into reality. From harmonising data and […]

The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define, benchmark, and standardize meaningful KPIs that capture the true value of Medical Affairs […]

As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements, the upcoming EHDS regulation marks a landmark move towards data sharing, and increasingly robust AI […]

Now in its 8th year, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they […]

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnerships & Capital With fast, cost-effective clinical infrastructure, generous government incentives, […]

The 7th Annual AI in Drug Discovery Conference, hosted by SAE Media Group, takes place 9-10 March 2026 at Hilton London Kensington. This event explores how AI, machine learning, and […]

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads […]

The 11th Innate Killer Summit stands at the forefront of innovation in innate immunity, offering an unparalleled platform for exploring the next generation of NK cell-based therapies and innate immune […]

Immune Resetting: B-Cell Mediated & Beyond Summit is redefining the conversation around immune modulation and therapeutic innovation. As the global biopharma industry accelerates its focus on autoimmune and inflammatory diseases, […]

Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by resilient teams who remain committed to transforming patients’ lives. With […]

Returning to Boston in April 2026, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest […]

Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity […]

The SmartLab Exchange USA is an exclusive, invitation-only event designed for senior laboratory, R&D, and digital transformation leaders across pharma, biotech, chemicals, FMCG, and food & beverage. This two-day forum […]

As part of SAE’s leading PFS Series, the 2026 conference will once again bring together top experts, industry leaders, and innovators for a three-days of key insights and networking. The […]

The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical, bioanalytical, […]

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy. To shine […]